Schreiner develops medication adherence technology

According to Schreiner, up to 50 percent of patients involved in clinical trials do not adhere to the prescribed dosage regimen, resulting in distorted outcomes such as insufficient drug efficacy or underestimated frequency of side effects. Ultimately, these adverse events can delay time to market. 

Schreiner's therapy monitoring technology consists of Smart Blister Packs for tablets and Smart Kit Boxes for vials and syringes with sensor technology linked to matching software. When a patient extracts a tablet from a cavity or removes a vial from a compartment, real-time data are generated such as time of removal, compartment from which the product is extracted, and dose. This information is automatically stored and transmitted to a database via a smartphone app or reader.

The electronic therapy management is completed by the matching data platform from Aardex, enabling the visualization and analysis of the data from the dosing history.

The new technology enhances compliance with the requirements and dosing regimens of the Clinical Trial Protocols proposed by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, it enables the detection of structural deficiencies and collecting essential data about patient behavior that can be used for marketing strategies and other purposes. 

‘Our partnership with Aardex combines Schreiner MediPharm's unique smart packaging technology, which can be scaled up via roll-to-roll processes into large commercial volumes, with the necessary intelligence from Aardex. This cooperation will enable us to leverage the full potential of medication adherence in clinical trials and commercial environments. We look forward to supporting our customers with a complete solution and joint consultancy expertise,’ commented Stefan Wiedemann, senior director for strategic marketing and business development at Schreiner MediPharm.

‘All of Schreiner MediPharm’s smart package solutions are now compatible with the Aardex Mems software to manage patient adherence in clinical trials. This partnership reinforces the position of the Aardex digital interface and back-end platform as a unique solution to collect, analyze, and manage medication adherence data in clinical trials. It is aligned with our strategy to open the Aardex digital platform to a variety of smart pharmaceutical packages and smart devices to cover all routes of drug administration,’ concluded Bernard Vrijens, co-CEO and scientific lead of Aardex Group.